Phase 2 N=278 Safety and Immunogenicity Study of Rift Valley Fever Vaccine
Rift Valley Fever
Primary: Safety: All Incidences of Erythema — 15; 10; 0 number of events
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=20 Safety/Immunogenicity/Genetic Drift of MP-12 Rift Valley Fever Vaccine
Rift Valley Fever
Primary: Safety as Measured by the Number of Adverse Events — 22; 130 AEs
Phase 1 N=60 FMP2.1/AS02A: Rabies Vaccine Malaria-Experienced Adults in Bandiagara, Mali
Malaria · Plasmodium Falciparum Malaria
Primary: Safety and Reactogenicity (SAEs and AEs) — 45; 53; 22; 37 Number of events
Phase 1 N=40 Ebola Sudan Chimpanzee Adenovirus Vector Vaccine in Healthy Adults
Ebola Virus
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 7 Days After the cAd3-EBO S Vaccine Administration — 3; 3; 6; 16 Participants
Phase 2 N=115 VSV-ZEBOV Geneva Vaccine Trial
Ebolavirus Disease
Primary: Titers of ZEBOV-specific IgG Antibodies — 1227; 25; 344.5 ELISA units per ml
Phase 2 N=400 Double-blind, Randomized, Controlled Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine
Malaria, Falciparum
Primary: Subjects Time to First Clinical Episode of P Falciparum Malaria During the Efficacy Follow-up Period Adjusted for Time at Risk - Intent to Treat (ITT) Population — 107…
Phase 4 N=22 Special Access Program IMVAMUNE®
Vaccination
Primary: ELISA Seropositivity Rate — 40.9; 100.0 percentage of subjects
Phase 3 N=8,651 STRIVE (Sierra Leone Trial to Introduce a Vaccine Against Ebola)
Hemorrhagic Fever, Ebola
Primary: Laboratory-confirmed Ebola (Study Diagnostics) — 0; 0 Participants
Phase 1 N=39 Safety and Immunogenicity of Prime-Boost Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-002)
Ebola Viruses
Primary: Percentage of Participants With 1 or More Unsolicited AE : Vaccination 1 — 60.0; 70.0; 50.0; 44.4 Percentage of participants
Phase 2 N=34 Study of a Live Attenuated Chikungunya Vaccine in a Previously Epidemic Area
Chikungunya
Primary: Number of Participants With AEs and Abnormal Lab Values, Vital Signs, and PE Findings — 11; 13; 4; 4 subjects
Phase 2 N=10 Safety Evaluation of a Q-fever Vaccine, NDBR 105
Q Fever
Primary: The Adverse Reaction and Occupational Illness Endpoint Measurements in This Q Fever NDBR 105 Vaccine Study Will be Evaluated for All Intent-to-treat Volunteers. — 10…
Phase 3 N=4,124 Repeat Ivermectin Mass Drug Administrations for MALaria Control II
Malaria
Primary: Malaria Incidence — 0.0176; 0.0183 Malaria cases per person-week
Phase 1 N=30 VRC 313: A Trivalent Virus-like Particle (VLP) Encephalitis Vaccine (WEVEE) in Healthy Adults
Venezuelan Equine Encephalitis · Western Equine Encephalitis · Eastern Equine Encephalitis
Primary: Number of Subjects Reporting Local Reactogenicity Signs and Symptoms For 7 Days After Each Product Administration — 4; 2; 0; 1 Participants
Phase 2 N=320 Immunogenicity and Safety of a Purified Vero Rabies Vaccine
Rabies Virus
Primary: Rabies Virus Neutralizing Antibody (RVNA) Geometric Mean Titers (GMTs) Against Rabies Virus at Day 0 — 0.101; 0.100; 0.102; 0.101 international units per milliliter
Phase 1 N=26 Safety, Tolerability and Immunogenicity of Vaccine Candidate MVA-MERS-S
MERS (Middle East Respiratory Syndrome)
Primary: Percentage of Participants Experiencing Solicited Local or Systemic Reactogenicity as Defined by the Study Protocol — 10; 10 Participants
Phase 2 N=400 Phase II AMA-1 Malaria Vaccine FMP2.1/AS02A Trial in Mali
Plasmodium Falciparum Malaria
Primary: Number of Subjects Reporting Solicited Adverse Events During the 7-day Surveillance Period After the First Vaccination — 0; 5; 0; 12 Participants
Phase 1 N=40 Safety Study of Candidate Malaria Vaccine FMP1/AS02A in Healthy Adults in Bandiagara, Mali
Malaria
Primary: Number of Participants With Solicited Adverse Events by Immunization and Type — 8; 18; 4; 13 Participants
Phase 1 N=32 Safety and Efficacy of R0.6C Vaccine
Malaria · Malaria,Falciparum
Primary: Number of Serious Adverse Events and Grade 3 Adverse Events — 0; 0; 0; 0 adverse events
Phase 2 N=44 Respiratory Syncytial Virus - RSV Protocol
Bone Marrow Transplant Infection · Infection in Marrow Transplant Recipients · Respiratory Syncytial Virus Infections
Primary: Percentage of Participants With Progression to Lower Respiratory Tract Infection (LRI) — 8; 30; 10 percentage of participants
Phase 1 N=513 Placebo Controlled, Dose Response, Safety and Immunogenicity Study of Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-004)
Ebola Virus
Primary: Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity — 17.2; 21.9; 29.7; 45.3 Percentage of Participants
N/A N=300 Sylvatic Transmission of Zika, Dengue, and Chikungunya Viruses in Thailand and Cambodia
Dengue Fever · Zika · Vector-Borne Diseases
Primary: Assessment of DENV, ZIKV, CHIKV Seroprevalence Via Screening PRNT50 Titers in Cambodian Adults. — 300 Participants
Phase 1 N=135 Phase 1 Trial of a Malaria Vaccine in Young Kenyan Children
Plasmodium Falciparum Malaria
Primary: Occurrence of Solicited Symptoms During a 8 Day Follow-up Period After Each Vaccination — 24; 11; 35; 15 events
N/A N=19 Flavivirus Cross-priming Potential of IMOJEV
Japanese Encephalitis
Primary: Primary: Plasmablast Percentage of Total B Cells at 7 Days Post Vaccine — 1.36; 1.96; 1.69 percent plasmablasts of B cells
Phase 1 N=78 Study of the Transmission-Blocking Vaccine Pfs230D1-EPA/Matrix-M Against Malaria in Adults in Mali
Malaria,Falciparum
Primary: Number of Local and Systemic Adverse Events (AEs) to Assess the Safety of the Study Drug — 34; 24; 23; 16 Adverse Events